Investor Presentaiton

API FACILITES NATCO Strategically important business - develops APIs primarily for third party sales and also for captive consumption Portfolio of 45 (¹) active US DMFs with niche products under development Focus on complex oncology molecules. Other therapeutic areas of development includes CNS and Orphan indications Exports are focused on the US, EU, Latin America and RoW markets. In-house KSMs for several APIs a key competitive advantage MEKAGUDA TELANGANA Oncology API's and speciality products Approvals from USFDA, PMDA (Japan), COFEPRIS (Mexico), EDQM (Europe), ANVISA, WHO, EU GMP (Germany), CDSCO STRENGTHS Complex multi-step synthesis & scale-up Advanced synthetic/separation technologies Containment facility for handling High potency APIs Peptide (Solid phase) pharmaceuticals Oligo nucleotide Pharmaceuticals Well established process safety engineering lab (1) As of Sept 30, 2023 Last USFDA audit successfully completed and EIR received in September 2019 CHENNAI TAMIL NADU Dedicated for Oncology USFDA, CDSCO, WHO-GMP USFDA audit with Establishment Inspection Report (EIR) received in July 2019 9

View entire presentation